lunes, 20 de mayo de 2013

Guideline Recommendations for EGFR Mutation ... [Korean J Pathol. 2013] - PubMed - NCBI

2013 Apr;47(2):100-6. doi: 10.4132/KoreanJPathol.2013.47.2.100. Epub 2013 Apr 24.

Guideline Recommendations for EGFR Mutation Testing in Lung Cancer: Proposal of the Korean Cardiopulmonary Pathology Study Group.

Shim HS, Chung JH, Kim L, Chang S, Kim WS, Lee GK, Jung SH, Jang SJ.

Source

Department of Pathology, Yonsei University College of Medicine, Seoul, Korea.

Abstract

Mutations of the epidermal growth factor receptor (EGFR) are the strongest predictive factor for response to EGFR tyrosine kinase inhibitors (TKIs), such as gefitinib and erlotinib. EGFR TKIs are approved in Korea as a first-line treatment for lung cancer patients with mutated EGFR. Rapid and accurate EGFR mutation testing is essential for patient selection and establishing targeted therapies with EGFR TKIs. Thus, a standard set of guideline recommendations for EGFR mutation testing suitable for the Korean medical community is necessary. In this article, we propose a set of guideline recommendations for EGFR mutation testing that was discussed and approved by the Cardiopulmonary Pathology Study Group of the Korean Society of Pathologists.